180 related articles for article (PubMed ID: 20221574)
1. [Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].
Koch R; Sander CA
Hautarzt; 2010 Nov; 61(11):976-9. PubMed ID: 20221574
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
4. Follicular lymphoma: 2011 update on diagnosis and management.
Freedman A
Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
[TBL] [Abstract][Full Text] [Related]
5. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
7. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
[TBL] [Abstract][Full Text] [Related]
9. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
10. Disseminated juvenile xanthogranuloma associated with follicular lymphoma in an adult: successful treatment with chemotherapy and rituximab. A review of the literature.
Narváez-Moreno B; Pulpillo-Ruiz Á; De Zulueta-Dorado T; Conejo-Mir J
Actas Dermosifiliogr; 2013 Apr; 104(3):242-6. PubMed ID: 22681714
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
12. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.
Nabhan C; Smith SM; Kahl BS
Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083
[TBL] [Abstract][Full Text] [Related]
13. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.
Witzens-Harig M; Foá R; Di Rocco A; van Hazel G; Chamone DF; Rowe JM; Arcaini L; Poddubnaya I; Ho AD; Ivanova V; Vranovsky A; Thurley D; Oertel S
Ann Hematol; 2014 Oct; 93(10):1717-24. PubMed ID: 24824768
[TBL] [Abstract][Full Text] [Related]
14. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
15. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
Găman AM
Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
[TBL] [Abstract][Full Text] [Related]
16. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for the treatment of follicular lymphoma.
Cheah CY; Lingaratnam S; Seymour JF
Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
19. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
[TBL] [Abstract][Full Text] [Related]
20. Primary duodenal follicular lymphoma successfully treated with rituximab.
Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
